Long Non-Coding RNA H19 Expression in Leukemia Patients

Year 2023, , 35 - 40, 27.12.2023

Kadir Sinan Aslan , Sema Agüloğlu Fincan

https://doi.org/10.56484/iamr.1350443

Abstract

Abstract
Objective: BCR-ABL fusion gene occurs with the formation of translocations in the t(9;22) region of the Philadelphia (Ph) chromosome, which is used as a diagnostic biomarker in Chronic Myeloid Leukemia (CML). These abnormal genetic changes, which cover 15% of leukemias, reach dimensions that threaten human life. Recent studies have determined that thousands of genes expressed in differentiation and development processes contain non-protein-coding RNA with a regulatory role. Of these, the first discovered long noncoding RNA (LncRNA) H19 has been associated with its biological role, cell proliferation, apoptosis and metastasis Therefore, studies have been conducted considering that LncRNA H19 can be used as a biological marker in CML patients.
Method: For this study, blood from 72 CML patients over 18 years of age and 64 healthy individuals were used. After RNA isolation of each of these bloods and cDNAs were obtained, the expression levels of the LncRNA H19 gene were analyzed by Real Time PCR method.
Results: As a result of the expression study, it was found that LncRNA H19 gene expression increased 4.37 times and was upregulated in Bcr-Abl positive patients (p=0.414683).
Conclusion: In this study conducted in Diyarbakır region, we think that LncRNA H19, which is up-regulated in terms of CML profiles, can be used as a biological marker for new treatment applications.

Keywords

CML, RT-PCR, LncRNA H19, BCR-ABL

References

• Juliusson G, Lazarevic V, Hörstedt A, Hagberg O, Höglund M. Acute myeloid leukemia in the real world: why populationbased registries are needed. Blood. 2012; 119(17): 3890–3899. doi: 10.1182/blood-2011-12-379008.
• Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res 2012 Feb 15;18(4):930-7. doi: 10.1158/1078-0432.CCR-10-1613.
• Sessions J. Monitoring your patients with chronic myeloid leukemia. American journal of health-system pharmacy. 2006; 63(23_Supplement_8), S5-S9. doi:10.2146/ajhp060524
• Karaarslan, Z. Ö., & Serin, M. S. Hastalıkların tanı ve tedavi stratejilerinde miRNA ve diğer non-protein-coding RNA’lar. Mersin Üniversitesi Sağlık Bilimleri Dergisi. 2016; 9(3), 159-172.
• Guo G , Qingzheng Kang Q, Qinghuang Chen Q et al. High expression of long non-coding RNA H19 is required for efficient tumorigenesis induced by Bcr-Abl oncogene. FEBS Lett. 2014; 588(9):1780-1786. doi: 10.1016/j.febslet.2014.03.038.
• Brannan C.I, Dees E.C, Ingram R.S, Tilghman S.M. The Product of the H19 Gene May Function as an RNA, Mol. Cell Biol. 1990; 10(1):28-36. doi: 10.1128/mcb.10.1.28-36.1990.
• Raveh E, Matouk I.J, Gilon M, Hochberg A. The H19 Long non-coding RNA in cancer initiation, progression and metastasis - a proposed unifying theory. Mol Cancer. 2015; 14:1-14. doi: 10.1186/s12943-015-0458-2.
• National Library of Medicine. https://www.ncbi.nlm.nih.gov (16.08.2023)
• QIAGEN. https://geneglobe.qiagen.com (17.08.2023)
• Klattenhoff C, Scheuermann J.C, Surface L.E. et al. Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell. 2013; 152(3): 570–583. doi: 10.1016/j.cell.2013.01.003
• Bin X, Hongjian Y, Xiping Z, Bo C, Shifeng Y, Binbin T. Research progresses in roles of LncRNA and its relationships with breast cancer. Cancer. Cell Int. 2018;18(1):1-12. doi: 10.1186/s12935-018-0674-0.
• Chen D, Sun Q, Cheng X, et al. Genome‐wide analysis of long noncoding RNA (lnc RNA) expression in colorectal cancer tissues from patients with liver metastasis. Cancer medicine. 2016; 5(7):1629-1639. doi: 10.1002/cam4.738
• Rathinasamy B, Velmurugan, B.K. Role of lncRNAs in the cancer development and progression and their regulation by various phytochemicals. Biomedicine & Pharmacotherapy. 2018;(102):242–248. doi:10.1016/j.biopha.2018.03.077